09:10~10:00 Brca 突變的晚期乳癌及卵巢癌病人的治療考量 10:00~10:50 From triple-negative to Dx-positive breast cancer: Perspectives and experience with cancer immunotherapy for patients with metastatic triple negative disease 10:50~11:00 休息 11:00~11:50 Optimal 1L NSCLC treatment with Immunotherapy 11:50~13:00 午餐 13:00~13:50 Navigating HCC treatment decisions: What Do We Learn from Systemic Treatment 13:50~14:40 Evolving IO Combination Strategy in Frontline advanced NSCLC. 14:40~14:50 休息 14:50~15:40 A Good Start of Immunotherapy for Esophageal Cancer- Emerging Role and Future Perspectives. 15:40~16:00 Closing